HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Canc... by Goran Bencina, Elina Petrova, Demet Sönmez, Sonia Matos Pereira, Ioannis Dimitriadis, Stina Salomonsson

“…**Objective:** This review aimed to map HTA status, reimbursement restrictions, and patient access for 3 advanced prostate cancer indications across 23 European countries during 2011-2021. …”
Get full text

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer by Jennifer H. Gunter, Amy A. Lubik, Ian McKenzie, Michael Pollak, Colleen C. Nelson

“…Prostate cancer patients present a promising cohort for the exploration of insulin stabilising agents as adjunct treatments for hormone deprivation or enhancers of chemosensitivity for treatment of advanced prostate cancer.…”
Get full text

Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression by Jasper Van Goubergen, Miroslav Peřina, Florian Handle, Elisa Morales, Anika Kremer, Oliver Schmidt, Glen Kristiansen, Marcus V. Cronauer, Frédéric R. Santer

“…In advanced prostate cancer (PC), in particular after acquisition of resistance to androgen receptor (AR) signaling inhibitors (ARSI), upregulation of AR splice variants compromises endocrine therapy efficiency. …”
Get full text

Delphi study to identify consensus on patient selection for hydrogel rectal spacer use during radiation therapy for prostate cancer in the UK by Amit Bahl, Suneil Jain, Albert Edwards, Rhodri Saunders, Clive Peedell, Heather Ann Payne, James Andrew Thomas, Prantik Das, Amanda Hansson Hedblom, Emily Woodward

“…Objectives To identify consensus on patient prioritisation for rectal hydrogel spacer use during radiation therapy for the treatment of prostate cancer in the UK.Design Delphi study consisting of two rounds of online questionnaires, two virtual advisory board meetings and a final online questionnaire.Setting Radical radiation therapy for localised and locally advanced prostate cancer in the UK.Participants Six leading clinical oncologists and one urologist from across the UK.Interventions Rectal hydrogel spacer.Primary and secondary outcome measures None reported.Results The panel reached consensus on the importance of minimising toxicity for treatments with curative intent and that even low-grade toxicity-related adverse events can significantly impact quality of life. …”
Get full text

Elucidating the role of pyrimidine metabolism in prostate cancer and its therapeutic implications by Liang Huang, Yu Xie, Shusuan Jiang, Kan Liu, Zhihao Ming, Hong Shan

“…Targeting this metabolic pathway offers a promising strategy for the development of new therapeutic approaches, particularly for overcoming drug resistance and improving outcomes in patients with advanced prostate cancer.…”
Get full text

EHMT2‐mediated R‐loop formation promotes the malignant progression of prostate cancer via activating Aurora B by Yuyang Zhang, Mingqin Su, Yiming Chen, Li Cui, Wei Xia, Renfang Xu, Dong Xue, Xiansheng Zhang, Xingliang Feng

“…Key points Euchromatic histone lysine methyltransferase 2 (EHMT2) is overexpressed in advanced prostate cancer, restraining catastrophic chromosomal instability (CIN) and enhancing cell fitness. …”
Get full text

Reciprocal regulation between DNMT3A/3B and microRNAs miRs-299-3p/-30e is a causal factor for the downregulation of microRNAs targeting androgen receptor in prostate cancer by Kavya Ganapathy, Christian F. Harrs, Samuel Harris, Stephen J. Staklinski, Ayman Khatib, Jong Y. Park, Ratna Chakrabarti

“…We previously reported that microRNAs (miRNA)-299-3p and −30e target androgen receptor (AR) and are downregulated in advanced prostate cancer (PCa). Here we report that miR-34c, an AR targeting miRNA and miR-299-3p, both are differentially downregulated in PCa cells from African American (AA) and Caucasian American (CA) patients due to disparate promoter hypermethylation in these miRNA genes. …”
Get full text

Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression by Elisa Carouge, Clémence Burnichon, Martin Figeac, Shéhérazade Sebda, Nathalie Vanpouille, Audrey Vinchent, Marie‐José Truong, Martine Duterque‐Coquillaud, David Tulasne, Anne Chotteau‐Lelièvre

“…Here, we show, using cell models of advanced prostate cancer, that ETS translocation variant 1 (ETV1) and transcriptional regulator ERG (ERG) transcription factors (members of the ETS family) promote tumour properties, and that activation of MET signalling enhances these effects. …”
Get full text

Sideroflexin family genes were dysregulated and associated with tumor progression in prostate cancers by Hua Huang, Huibo Lian, Wang Liu, Benyi Li, Runzhi Zhu, Haiyan Shao

“…SFXN4 expression was identified as a diagnostic biomarker and prognostic factor for unfavorite survival outcomes. In advanced prostate cancers, SFXN2/4 expressions were positively correlated with the androgen receptor signaling activity but negatively correlated with the neuroendocrinal features. …”
Get full text

Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells by Bin Han, Naohiro Fujimoto, Mizuki Kobayashi, Tetsuro Matsumoto

“…Most advanced prostate cancers progress to castration resistant prostate cancer (CRPC) after a few years of androgen deprivation therapy and the prognosis of patients with CRPC is poor. …”
Get full text

SNP rs9364554 Modulates Androgen Receptor Binding and Drug Response in Prostate Cancer by Yuqian Yan, Lei Shi, Tao Ma, Liguo Wang, Haojie Huang

“…More importantly, we found that this SNP has different binding affinities with transcription factors, specifically FOXA1 and AR, which significantly affects their regulation of <i>SLC22A3</i> transcription. (4) Conclusions: Our findings highlight the potential of using this SNP as a biomarker for predicting chemotherapeutic outcomes and uncover possible mechanisms underlying drug resistance in advanced prostate cancers. More importantly, it provides a clinical foundation for targeting FOXA1 to enhance drug efficacy in prostate cancer patients.…”
Get full text